Indivior Achieves Fourth Quarter Profits and Records Revenue Growth in FY22; Additional Plans US List

(RTTNews) – Pharmaceutical company Indivior Plc (INDV.L) reported on Wednesday that its fourth quarter net profit was $35 million, compared to a loss of $13 million last year. Earnings per share were 5 cents, compared to a loss of 2 cents a year ago.

Adjusted net income was $25 million or 3 cents per share, compared to $26 million or 4 cents per share a year ago.

Net sales increased 20% to $222 million from $185 million a year earlier.

For fiscal 2022, the company expects net revenue in the range of $840 million to $900 million, a 10% growth from last year at the midpoint. The outlook reflects the strong growth of SUBLOCADE and the relative stability of SUBOXONE Film’s market share.

Adjusted operating profit is expected to be broadly similar to last year’s adjusted operating profit of $187 million.

Additionally, Mark Crossley, CEO of Indivior, said: “Our preliminary view is that an additional US listing is likely to benefit the group’s profile and visibility, as around 80% of the group’s net income is generated in the United States. We recognize this is an important topic, and the Board and management intend to consult extensively with shareholders before deciding on any future course. »

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.